Riddhi Upadhyay

The gut-brain axis in Alzheimer’s and Parkinson’s diseases: a comparative perspective

Global health challenges associated with neurodegenerative disorders are increasing, prompting growing interest in the gut-brain axis (GBA) as a key contributor to disease pathogenesis. The GBA represents a bidirectional communication network linking the gut microbiota, immune signalling pathways, metabolic processes,...

Chemokine receptor CX3CR1 modulates microglial activity through Tau and amyloid-β interactions in Alzheimer's disease.

GFAP and the genetic code of astrocyte activation in Alzheimer's disease.

GFAP is an efficient biomarker in CSF, plasma, and saliva, which is associated with amyloid pathology, cognitive impairment, and AD, and can be used to extract significant information about AD mechanisms and find opportunities to identify diagnosis, prognosis and therapy.

Signaling cascades of microtubule-associated protein Tau in Alzheimer's disease.

This review highlights the major signaling cascades involved in Tau PTMs and its interlinked role in mitochondrial damage in aging population in AD.

Microglial polarisation imbalance and receptor-targeted therapeutics in Parkinson's disease.

This network is interconnected, and understanding it is crucial in the creation of therapies that attempt to restore proteostasis, inhibit inflammation, and increase neurotrophic signalling to delay or prevent PD progression.

Small molecular therapeutic targets for neurodegenerative diseases.

A deeper understanding of aging-associated molecular dysfunction is essential to design sustainable, disease-modifying therapeutics with cross-disease relevance.